Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Ladiratuzumab-Vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seattle Genetics
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.
- 13 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
- 05 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.